epinephrine

Supported epinephrine identification

Record the claimed identity and the evidence supporting discrimination from related catecholamines.

1. Which reference identifier or chemical structure does this use of epinephrine or adrenaline denote? definition
2. What test or composition record supports epinephrine identity, and can it distinguish norepinephrine, dopamine and relevant interferents? measurement

Chemical equivalence boundaries

Require explicit stereochemical and chemical-form information before equating two epinephrine materials.

1. What stereochemical composition is specified or measured, and what remains unknown? measurement
2. Is the material a free base or an identified salt, and does its stated amount refer to that form or to epinephrine equivalents? definition

Epinephrine occurrence provenance

Record whether the agent is assessing a supplied material, a formulated ingredient or an analyte occurrence without inferring origin from identity alone.

1. Is this occurrence a manufactured material, formulation ingredient, reference standard or biological analyte? definition
2. Which batch, supplier, preparation record or specimen links support its origin, and is endogenous versus administered origin established or unknown? provenance

Contextualised epinephrine result

Keep the reported result attached to its matrix, collection conditions and assay limitations.

1. What specimen matrix, collection time or interval, preservation history and relevant administered-epinephrine history accompany the result? provenance
2. What method, units, detection limits and laboratory interpretation criteria apply, and where must interpretation pass to a clinical model? boundary

Unambiguous active content

Represent epinephrine content with explicit units, volume and chemical basis while preserving the original label expression.

1. What is the epinephrine concentration in explicit mass-per-volume units, and what chemical basis does it use? measurement
2. What total active amount follows from the verified material quantity, and is a stated delivered amount a separate product or device claim? boundary

Formulation-specific suitability

Record excipients, co-active ingredients and preparation requirements at the product level rather than generalising them to all epinephrine.

1. Which solvent, preservatives, sulfites or other antioxidants, and co-active ingredients are present in this preparation? definition
2. Which exact product instructions support the proposed route, diluent and final concentration? action

Quality evidence and limits

Assess assay, impurities and visible condition against an applicable specification while retaining gaps in evidence.

1. What assay and related-substance results support the stated epinephrine potency and purity, using which methods and acceptance criteria? measurement
2. What colour, clarity, particulate or container-integrity observations were recorded, and which quality attributes remain untested? measurement

Supported remaining usability

Distinguish unopened expiry from evidence supporting use after an excursion, opening or preparation step.

1. What temperature, light exposure, opening, dilution and container-transfer history is known for this epinephrine material? provenance
2. Which product-specific or validated stability evidence supports continued use, quarantine or rejection after that history? action

Purpose-bound use decision

Separate chemical suitability from permission to use a particular epinephrine preparation in a clinical or laboratory activity.

1. Is the proposed use analytical, experimental, manufacturing-related or clinical, and what grade and quality evidence does it require? boundary
2. Which current product label, validated procedure or authorised clinical instruction governs the proposed action? action

Verified operation or escalation

Support a proposed operation only to the extent established by concentration, formulation, condition and external instruction.

1. Before transfer or dilution, have source strength, epinephrine-equivalent amount, final volume and formulation compatibility been verified? action
2. What unresolved discrepancy requires clarification, quarantine or rejection, and which linked workflow handles urgent clinical decisions or disposal? action

Kinds and varieties

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Endogenous adrenal-medullary hormone (circulating epinephrine of the fight-or-flight response)
• Pharmaceutical L-epinephrine (the levorotatory free base used as the drug substance)
• Epinephrine hydrochloride injection
• Epinephrine bitartrate (ophthalmic and some parenteral salts; tartrate-containing products are avoided intraocularly)
• Racemic epinephrine for nebulization (croup), as distinct from L-epinephrine
• 1 mg/mL (historically 1:1000) intramuscular/subcutaneous anaphylaxis presentation
• 0.1 mg/mL (historically 1:10,000) intravenous/intraosseous cardiac-arrest presentation
• Community self-administration products (auto-injectors at 0.1/0.15/0.3 mg and epinephrine nasal spray)

1. Which of these kinds and varieties hold for the sense of epinephrine this model covers, and on what evidence? provenance

Identifiers and schemes

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Wikidata - Q132621 - Item for the molecule (hormone and drug).
• CAS Registry Number - 51-43-4 - Free base; salt forms have different CAS numbers.
• PubChem CID - 5816 - NCBI PubChem compound.
• FDA UNII - YKH834O4BH - Substance identifier in FDA SRS.
• INN / USAN - epinephrine - WHO International Nonproprietary Name and United States Adopted Name; BAN is adrenaline.
• ATC - A01AD01 | B02BC09 | C01CA24 | R01AA14 | R03AA01 | S01EA01 - WHO Anatomical Therapeutic Chemical codes by use (stomatological, haemostatic, cardiac stimulant, nasal, inhalant, ophthalmic).
• DrugBank - DB00668 - Drug record for the pharmaceutical substance.
• ChEBI - CHEBI:28918 - Chemical Entities of Biological Interest.
• InChIKey - UCTWMZQNUQWSLP-VIFPVBQESA-N - Stereospecific key for (R)-epinephrine.
• EC number - 200-098-7 - ECHA substance information 100.000.090.

1. Which of these identifiers and schemes hold for the sense of epinephrine this model covers, and on what evidence? provenance

Standards and regulation

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• WHO International Nonproprietary Name: epinephrine (adrenaline listed as a synonym); British Approved Name and European Pharmacopoeia title: adrenaline.
• WHO Model List of Essential Medicines (epinephrine/adrenaline as a core emergency medicine).
• WHO Collaborating Centre for Drug Statistics Methodology: ATC codes A01AD01, B02BC09, C01CA24, R01AA14, R03AA01, S01EA01.
• US FDA: prescription-only; approved for type I hypersensitivity including anaphylaxis, hypotension of septic shock, and intraocular mydriasis; auto-injectors and nasal spray (neffy) are labelled products.
• EMA: Rx-only (e.g. Eurneffy EPAR for nasal epinephrine); UK MHRA: POM, typically labelled adrenaline (epinephrine).
• Australia: SUSMP Schedule 4 (prescription); pregnancy category A.
• American Heart Association ACLS/PALS guidelines: 1 mg IV/IO every 3-5 min in adult cardiac arrest; 0.01 mg/kg (max 1 mg) in paediatric arrest.
• Surviving Sepsis Campaign 2021: add epinephrine when mean arterial pressure remains inadequate on norepinephrine plus vasopressin.
• AAAAI/ACAAI anaphylaxis practice parameters: first-line intramuscular epinephrine and prescription of auto-injectors for at-risk patients.

1. Which of these standards and regulation hold for the sense of epinephrine this model covers, and on what evidence? provenance

Real-world use

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Intramuscular injection into the anterolateral thigh (auto-injector or 1 mg/mL ampoule) as first-line treatment of anaphylaxis in the community and emergency department.
• Intravenous or intraosseous 0.1 mg/mL boluses during cardiac arrest as part of ACLS/PALS, including prehospital EMT use of prefilled syringes.
• Titrated intravenous infusion for vasodilatory/septic shock after norepinephrine (and often vasopressin).
• Nebulized racemic or L-epinephrine for croup, and as adjunct bronchodilation in severe asthma unresponsive to standard therapy.
• Added to local-anaesthetic blocks for vasoconstriction and prolonged duration; used in ophthalmic irrigation or as an intracameral bolus for mydriasis during intraocular surgery.
• Intranasal spray (2 mg into one nostril, repeat after 5 min if needed) as a needle-free community alternative.
• Endotracheal administration (higher dose) when intravenous or intraosseous access is not yet available, including neonatal resuscitation.
• Measured, usually via metabolites (metanephrines), in the biochemical work-up of pheochromocytoma, hypoglycaemia, and myocardial infarction.

1. Which of these real-world use hold for the sense of epinephrine this model covers, and on what evidence? provenance

Typical measurements

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Molecular mass (free base) - 183.207 - g/mol
• Plasma half-life - 2-5 - min
• Adult intramuscular anaphylaxis dose - 0.3-0.5 - mg
• Adult cardiac-arrest IV/IO bolus - 1 mg every 3-5 min - mg
• Paediatric cardiac-arrest IV/IO dose - 0.01 (maximum 1 mg per dose) - mg/kg
• Septic-shock intravenous infusion - 0.05-2 - µg/kg/min
• Common injectable concentrations - 0.1 (cardiac 1:10,000) and 1 (anaphylaxis 1:1000) - mg/mL
• Auto-injector labelled doses - 0.1, 0.15, or 0.3 - mg

1. Which of these typical measurements hold for the sense of epinephrine this model covers, and on what evidence? provenance

Failure modes and hazards

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Wrong-concentration error: giving 1 mg/mL (1:1000) intravenously instead of 0.1 mg/mL (1:10,000), causing overdose with arrhythmia, myocardial ischaemia, pulmonary oedema, lactic acidosis, or Takotsubo cardiomyopathy.
• Delayed or omitted intramuscular epinephrine in anaphylaxis, a leading contributor to fatal outcomes.
• Extravasation of an infusion causing local ischaemia and tissue necrosis; phentolamine infiltration is the usual rescue.
• Injection into end-arterial sites (digits, nose, penis, toes) with risk of ischaemic injury.
• Expected sympathomimetic toxicity: tachycardia, hypertension, arrhythmia, vasospasm, angina, tremor, anxiety, hyperglycaemia, hypokalaemia.
• Potentiation by MAO inhibitors, COMT inhibitors, tricyclic antidepressants, and some antihistamines; antagonism or unopposed α-effects with β-blockers; increased arrhythmogenicity with halogenated anaesthetics and cardiac glycosides.
• Relative contraindication in catecholaminergic polymorphic ventricular tachycardia, where epinephrine can trigger arrest.
• Undiluted or bisulfite-containing intraocular use damaging corneal endothelium; epinephrine-driven lactate production confounding septic-shock lactate trends.
• Product failure: oxidation (pink/brown catechol discoloration) with loss of potency; auto-injector misuse, clothing, expiry, or under-dosing in larger patients.
• In out-of-hospital cardiac arrest, epinephrine can raise 30-day survival without improving favourable neurological outcome (PARAMEDIC2).

1. Which of these failure modes and hazards hold for the sense of epinephrine this model covers, and on what evidence? provenance

Regional variation

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• United States: official generic and FDA labelling is epinephrine (Adrenalin was a Parke-Davis trademark); clinical speech matches the label.
• United Kingdom and much of Europe, Australia, and Japan: clinicians say adrenaline; UK MHRA communications commonly write adrenaline (epinephrine); European Pharmacopoeia title is adrenaline.
• WHO INN remains epinephrine, so international product names, ATC, and many registries use epinephrine even where bedside language is adrenaline.
• Ratio labelling (1:1000 vs 1:10,000) is still common in some emergency systems and is being replaced by mg/mL on many modern labels to cut dosing errors.
• Community devices differ by market (EpiPen, Auvi-Q/Allerject, Jext, Anapen, and nasal sprays such as neffy/Eurneffy), as do auto-injector dose steps for infants.

1. Which of these regional variation hold for the sense of epinephrine this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

• Norepinephrine (noradrenaline) - Lacks the N-methyl of epinephrine, so it is mainly an α1/β1 agonist with little β2 activity; first-line vasopressor in septic shock rather than first-line for anaphylaxis or cardiac arrest. Separated by structure (N-methyl) and by LC-MS/MS or immunoassay of the two catecholamines and their metanephrines.
• Dopamine - The biosynthetic precursor; acts on dopamine receptors as well as adrenergic receptors and is used at different infusion ranges for shock. Chemical test: dopamine has no β-hydroxy or N-methyl of epinephrine (C8 vs C9 catecholamine).
• Ephedrine - A mixed-acting, non-catechol phenethylamine (no 3,4-dihydroxy ring) with oral activity and a longer duration; Wikipedia explicitly warns against confusing the names. Catechol functional-group test or mass spectrum separates them.
• Phenylephrine - Selective α1 agonist used as a vasopressor and decongestant; lacks the catechol 3,4-dihydroxy pattern and epinephrine's β-agonist cardiac and bronchial effects.
• Isoprenaline (isoproterenol) - The N-isopropyl analogue and a selective β-agonist (bradycardia/heart block), not a mixed α/β emergency pressor. Distinguished by the N-substituent (isopropyl vs methyl).
• Metanephrine - The COMT metabolite measured in plasma or urine for pheochromocytoma; not the parent hormone and not a resuscitation drug.

1. Which of these neighbouring kinds and how to tell them apart hold for the sense of epinephrine this model covers, and on what evidence? provenance